Health and Healthcare

Exelixis : EXEL

All Exelixis Articles

61 Articles

Chris Lange | Sep 8, 2016 at 8:05 AM EDT

Key FDA Decisions and Trial Results Expected in October

24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These…

Lee Jackson | May 15, 2016 at 10:05 AM EDT

Energy Insiders Keep Buying Shares as Oil Rises: Western Refining, Summit Midstream, Weatherford International and More

As the markets continue to stumble through May, and the volatility appears to be creeping up some, the end of…

Trey Thoelcke | May 5, 2016 at 7:35 AM EDT

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an…

Chris Lange | Feb 1, 2016 at 9:05 AM EST

Exelixis Rises on Positive Late-Stage Trial Results

Exelixis shares were rising early Monday following the release of positive results from its late-stage trial of cabozantinib.

Chris Lange | Jan 5, 2016 at 12:35 PM EST

Exelixis Posts Positive Late Stage Results in METEOR trial

Exelixis Inc. (NASDAQ: EXEL) was up slightly in Tuesday’s trading session following positive results from a late stage trial. The…

Lee Jackson | Dec 1, 2015 at 8:25 AM EST

Huge PowerShares ETF Rebalance Means Massive Buying for 4 Biotech Stocks

On the close Tuesday, the PowerShares Dynamic exchange traded funds (ETFs) are set for a rebalance. These four stocks that…

Chris Lange | Aug 6, 2015 at 2:20 PM EDT

5 Big FDA Decisions Expected in August

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and…

Chris Lange | Jul 21, 2015 at 5:29 PM EDT

How Exelixis Used Good News to Raise Over $100 Million in New Capital

It appears that Exelixis assumed now would be the best time to dilute following its most recent successful in clinical…

Chris Lange | Jul 20, 2015 at 10:35 AM EDT

Is Exelixis a Buyout Target Again?

The most recent clinical trial results may have put Exelixis back on the map as a potential buyout.

Chris Lange | Jun 7, 2015 at 9:10 AM EDT

How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer

24/7 Wall St. has taken a look at some of the major ASCO winners over the past week and how…

Chris Lange | Jun 1, 2015 at 9:40 AM EDT

6 Key Cancer Winners From ASCO Presentations

24/7 Wall St. has taken a look at a few of the major ASCO winners so far. Color and background…

Jon C. Ogg | Sep 2, 2014 at 10:40 AM EDT

After the Exelixis Implosion, Is There Anything Left Ahead?

Exelixis is seeing an outright implosion in its stock after news of its Phase 3 metastatic prostate cancer not meeting…

Jon C. Ogg | Sep 2, 2014 at 8:15 AM EDT

Top Analyst Upgrades and Downgrades: Avago, Exelixis, Gap, Groupon, Staples, Tesla and More

These are the top analyst upgrades and downgrades from 24/7 Wall St. for Tuesday, September 2, 2014.

Paul Ausick | Jul 14, 2014 at 4:24 PM EDT

Why the Exelixis Cancer Trial News Matters This Time

ThinkstockCancer treatment developer Exelixis Inc. (NASDAQ: EXEL) is trading very heavy volume today and getting a sharp price boost following…

Jon C. Ogg | Mar 26, 2014 at 12:05 PM EDT

Exelixis Enters the Danger Zone

Exelixis may have a while longer before it gets to be a serious revenue stage company. Its stock was crushed…

1 2 3 4 5

Exelixis : EXEL

All Exelixis Articles

Key FDA Decisions and Trial Results Expected in October

Energy Insiders Keep Buying Shares as Oil Rises: Western Refining, Summit Midstream, Weatherford International and More

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

Exelixis Rises on Positive Late-Stage Trial Results

Exelixis Posts Positive Late Stage Results in METEOR trial

Huge PowerShares ETF Rebalance Means Massive Buying for 4 Biotech Stocks

5 Big FDA Decisions Expected in August

How Exelixis Used Good News to Raise Over $100 Million in New Capital

Is Exelixis a Buyout Target Again?

How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer

6 Key Cancer Winners From ASCO Presentations

After the Exelixis Implosion, Is There Anything Left Ahead?

Top Analyst Upgrades and Downgrades: Avago, Exelixis, Gap, Groupon, Staples, Tesla and More

Why the Exelixis Cancer Trial News Matters This Time

Exelixis Enters the Danger Zone

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

“Did you buy It from the mob?”: Dave Ramsey hosts floored by 21-year-old’s 30% truck loan

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan

Ripple’s $1.25 Billion Hidden Road Acquisition: One Year On, What’s Changed?

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

Exelixis : EXEL

All Exelixis Articles

Key FDA Decisions and Trial Results Expected in October

Energy Insiders Keep Buying Shares as Oil Rises: Western Refining, Summit Midstream, Weatherford International and More

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

Exelixis Rises on Positive Late-Stage Trial Results

Exelixis Posts Positive Late Stage Results in METEOR trial

Huge PowerShares ETF Rebalance Means Massive Buying for 4 Biotech Stocks

5 Big FDA Decisions Expected in August

How Exelixis Used Good News to Raise Over $100 Million in New Capital

Is Exelixis a Buyout Target Again?

How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer

6 Key Cancer Winners From ASCO Presentations

After the Exelixis Implosion, Is There Anything Left Ahead?

Top Analyst Upgrades and Downgrades: Avago, Exelixis, Gap, Groupon, Staples, Tesla and More

Why the Exelixis Cancer Trial News Matters This Time

Exelixis Enters the Danger Zone

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

“Did you buy It from the mob?”: Dave Ramsey hosts floored by 21-year-old’s 30% truck loan

Featured Reads

Why Your 401(k) Could Trigger a Tax Bomb in Retirement (And What to Do Now)

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan